arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2008-14-4-320-323arthyper-1249Research ArticleОБЗОРREVIEWГомоцистеинемия как фактор риска диабетической нефропатии у детей и подростковHomocysteinemia as a risk factor of diabetic nephropathy in children and adolescentsШуцкаяЖ. В.ShutskayaZh. V.zhanna_shuckaya@mail.ruГородской Диабетологический Центр для детей и подростков ГУЗ ГП44РоссияMunicipal Diabetes Center for Children and Adolescents, municipal clinics № 44Russian Federation200828082008144320323Copyright © Шуцкая Ж.В., 20082008Шуцкая Ж.В.Shutskaya Z.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1249

В статье обобщены данные литературы о влиянии гомоцистеинемии на развитие патологических изменений сосудов у пациентов с различными нозологическими формами, включая сахарный диабет типов 1 и 2. Обсуждается вопрос о роли повышенного уровня гомоцистеина как независимого фактора риска диабетической нефропатии у детей и подростков. Рассматриваются вопросы фармакологической коррекции гомоцистеинемии

This article summarizes data on homocysteinemia and its influence on vascular pathologic changes in patients with different diseases including diabetes type 1 and type 2. The role of homocystein as an independent risk factor for diabetic nephropathy in children and adolescents is discussed. The problem of homocysteinemia treatment is reviewed.

диабетическая нефропатиядетиподросткигомоцистеинемияDiabetic nephropathychildrenadolescentshomocysteinemiaReferencesMcCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.Montalescot G, Ankri A, Chadefaux-Vekemans B.: Plasma homocysteine and the extent of atherosclerosis in patients with coronary arthery disease. Int J Cardiol 1997;60:295-300.Montalescot G, Ankri A, Chadefaux-Vekemans B.: Plasma homocysteine and the extent of atherosclerosis in patients with coronary arthery disease. Int J Cardiol 1997;60:295-300.Дедов И. И., Кураева Т. Л., Петеркова В. А. Сахарный диабет у детей и подростков. М: ГЭОТАР Медиа;2007;96-99.Дедов И. И., Кураева Т. Л., Петеркова В. А. Сахарный диабет у детей и подростков. М: ГЭОТАР Медиа;2007;96-99.Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М: Универсум Паблишинг; 2000:80-98.Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М: Универсум Паблишинг; 2000:80-98.Finkelstein J. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.Finkelstein J. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.Костюченко Г.И., Баркаган З.С. Диагностика и методы коррекции гипергомоцистеинемии в кардиологической практике. Методические указания. 2003:20.Костюченко Г.И., Баркаган З.С. Диагностика и методы коррекции гипергомоцистеинемии в кардиологической практике. Методические указания. 2003:20.Chang L, Xu J, Yu F, Zhao J, Tang X, Tang C. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004;27(1):37-48.Chang L, Xu J, Yu F, Zhao J, Tang X, Tang C. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004;27(1):37-48.Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998;98:2520-26.Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998;98:2520-26.Blom H. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr 1998;57(2):131-34.Blom H. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr 1998;57(2):131-34.Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentrations in different European populations (EARS group). Atherosclerosis 1998;136:347-54.Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentrations in different European populations (EARS group). Atherosclerosis 1998;136:347-54.Ali N. S, Powell J., Swaminathan R., Markus H.S. The relantionship between MTHFR genotype, serum homocysteine and folat levels. Biochem Sos Trans 1997;25:386.Ali N. S, Powell J., Swaminathan R., Markus H.S. The relantionship between MTHFR genotype, serum homocysteine and folat levels. Biochem Sos Trans 1997;25:386.Fodinger M, Wagner OF, Horl WH, Sunder-Plassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001;59(78):238-42.Fodinger M, Wagner OF, Horl WH, Sunder-Plassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001;59(78):238-42.Refsum H, Smith AD. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:207.Refsum H, Smith AD. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:207.Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-26.Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-26.McCully КS. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 1998;279(5):392-93.McCully КS. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 1998;279(5):392-93.Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001;59(78):230-33.Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001;59(78):230-33.Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-72.Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-72.Bonaa KH, Njolstad I, Ueland PM. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578-88.Bonaa KH, Njolstad I, Ueland PM. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578-88.Arruda V, von Zuben P, Chiaparini L The mutation Ala-Val in methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Tromb Haemost 1997;77:818-21.Arruda V, von Zuben P, Chiaparini L The mutation Ala-Val in methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Tromb Haemost 1997;77:818-21.Kazemi M, Eshraghian K, Omrani G Homocysteine level and coronary artery disease. Angiology 2006;57(1):9-14.Kazemi M, Eshraghian K, Omrani G Homocysteine level and coronary artery disease. Angiology 2006;57(1):9-14.Boushey C, Beresford S, Omenn G, Motulsky A A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274(13):1049-1057.Boushey C, Beresford S, Omenn G, Motulsky A A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274(13):1049-1057.Stangl V, Baumann G, Stangl К. Coronary atherogenic risk factors in women. Eur Heart J 2002;23(22):1738-52.Stangl V, Baumann G, Stangl К. Coronary atherogenic risk factors in women. Eur Heart J 2002;23(22):1738-52.Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002;17(5):857-64.Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002;17(5):857-64.Bollander-Gonnaile C. Focus on homocysteine and the vitamin ivolved in its metabolism. Springer Verlag France 2002:217.Bollander-Gonnaile C. Focus on homocysteine and the vitamin ivolved in its metabolism. Springer Verlag France 2002:217.Neugebauer S., Baba T., Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 1997;34:473-74.Neugebauer S., Baba T., Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 1997;34:473-74.Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorfism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:452.Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorfism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:452.Kark J, Selhub J, Bostom A, Adler B, Rosenberg I. Plasma homocysteine and all-cause mortality in diabetes.Lancet 253:1936-37.Kark J, Selhub J, Bostom A, Adler B, Rosenberg I. Plasma homocysteine and all-cause mortality in diabetes.Lancet 253:1936-37.Jacobs R.L., House J.D., Brosnan M.E., Brosnen J.T.: Effects of streptozotocin-induced diabetes and insulin treatment on homocystein metabolism in the rat. Diabetes 1998;47:1967-70.Jacobs R.L., House J.D., Brosnan M.E., Brosnen J.T.: Effects of streptozotocin-induced diabetes and insulin treatment on homocystein metabolism in the rat. Diabetes 1998;47:1967-70.Schwartz E, Shcherbak N, Shutskaya Zh, Sheidina A, Larionova V Methylentetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Moleс gen and metabol 1999;68:375-78.Schwartz E, Shcherbak N, Shutskaya Zh, Sheidina A, Larionova V Methylentetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Moleс gen and metabol 1999;68:375-78.Шуцкая Ж. В., Башнина Е. Б., Савенкова Н. Д. Распространенность диабетической нефропатии у больных с аллельными вариантами C667T полиморфизма гена МТГФР по результатам 7-летнего катамнеза. Нефрология 2008;12(1):36-39.Шуцкая Ж. В., Башнина Е. Б., Савенкова Н. Д. Распространенность диабетической нефропатии у больных с аллельными вариантами C667T полиморфизма гена МТГФР по результатам 7-летнего катамнеза. Нефрология 2008;12(1):36-39.Matteucci E., Rossi L., Marini S. Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab Cardiovasc Dis 2002;12(4):184-89.Matteucci E., Rossi L., Marini S. Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab Cardiovasc Dis 2002;12(4):184-89.Потемкин В. В., Кубатиев А. А., Абрамова Е. А., Томилова Е. Н., Гудукина Г. Н. Роль гомоцистеина в патогенезе сосудистых осложнений при сахарном диабете 2-го типа. Проблемы эндокринологии. 2007;53(3):10-13.Потемкин В. В., Кубатиев А. А., Абрамова Е. А., Томилова Е. Н., Гудукина Г. Н. Роль гомоцистеина в патогенезе сосудистых осложнений при сахарном диабете 2-го типа. Проблемы эндокринологии. 2007;53(3):10-13.

The authors declare that there are no conflicts of interest present.